Utilizing Indicators CD117, CK7, and C7 to Detect Breast Cancer
Main Article Content
Abstract
Background: Breast cancer is a major global health issue, becoming one of the biggest causes deaths for women around the world, and the most costly type of cancer to treat. Breast cancer is typically diagnosed through a biopsy, an operation that causes the patient an extensive amount of pain and suffering. Recently, studies have focused on using biomarkers to predict and diagnose some types of cancer, including breast cancer. The goal of this study aims to use the blood samples of patients to identify breast cancer using the markers CD117, CK7, and C7.
Methods: the case-control study of 62 participants. 31 healthy controls and 31 patients with cancer meeting inclusion criteria, ranging in age from 30 to 74 years. An enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of CD117, CK7and C7 biomarkers.
Results: the results showed Statistically significant difference P value (< 0.05) between Breast group and control group for BMI, CLDN7 serum, CLDN7 tissue, CK7 serum, CK7 Tissue, CD117 serum and CD117 tissue. Also, shown non- significant difference P value (> 0.05) for Age.
Conclusion: As a result of their various concentrations, the C7, CK7, and CD117 biomarkers all have the potential to be utilized to diagnose breast cancer, however only C7 and CK7 have decreasing concentrations in breast cancer compared to a concentration (CD117) that is rising.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. S. J. Seidler and D. Huber, “Overview of Diagnosis and Treatment of Breast Cancer in Young Women,” EC Gynaecol., vol. 2, no. March, pp. 18–25, 2020.
II. A. Huber, S. J. Seidler, and D. E. Huber, “Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series,” Eur. J. Breast Heal., vol. 16, no. 2, pp. 129–136, 2020, doi: 10.5152/ejbh.2020.5297.
III. L. Wilkinson and T. Gathani, “Understanding breast cancer as a global health concern,” Br. J. Radiol., vol. 95, no. 1130, pp. 7–9, 2022, doi: 10.1259/BJR.20211033.
IV. A. Radhi, M. Thuwaini, and H. Abbas, “Clinical Significance of Some Tumour Biomarkers in the Diagnosis of Breast Cancer in Comparison with Histopathological Biopsy,” pp. 2–7, 2022, doi: 10.4108/eai.7-9-2021.2314939.
V. M. Arnold et al., “Current and future burden of breast cancer: Global statistics for 2020 and 2040,” Breast, vol. 66, no. September, pp. 15–23, 2022, doi: 10.1016/j.breast.2022.08.010.
VI. R. H. Lin, C. S. Lin, C. L. Chuang, B. K. Kujabi, and Y. C. Chen, “Breast Cancer Survival Analysis Model,” Appl. Sci., vol. 12, no. 4, pp. 1–19, 2022, doi: 10.3390/app12041971.
VII. WHO and World Health Organisation, “SDGs Sustainable Development Goals,” 2022. [Online]. Available: http://apps.who.int/bookorders.
VIII. W. K. Ho et al., “European polygenic risk score for prediction of breast cancer shows similar performance in Asian women,” Nat. Commun., vol. 11, no. 1, pp. 1–11, 2020, doi: 10.1038/s41467-020-17680-w.
IX. E. Marrazzo et al., “Mucinous breast cancer: A narrative review of the literature and a retrospective tertiary single-centre analysis,” Breast, vol. 49, pp. 87–92, 2020, doi: 10.1016/j.breast.2019.11.002.
X. M. Piechocki et al., “Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980–2018),” Clin. Epidemiol., vol. 14, pp. 95–114, 2022, doi: 10.2147/CLEP.S330081.
XI. M. F. Atoum, F. Alzoughool, and H. Al-Hourani, “Linkage Between Obesity Leptin and Breast Cancer,” Breast Cancer: Basic and Clinical Research, vol. 14. 2020.
doi: 10.1177/1178223419898458.
XII. M. F. Atoum and A. A. H. Alparrey, “Association of Leptin Receptor Q223R Gene Polymorphism and Breast Cancer Patients: A Case Control Study,” Asian Pacific J. Cancer Prev., vol. 23, no. 1, pp. 177–182, 2022,
doi: 10.31557/APJCP.2022.23.1.177.
XIII. P. R. Hollis, R. J. Mobley, J. Bhuju, A. N. Abell, C. H. Sutter, and T. R. Sutter, “CYP1B1 Augments the Mesenchymal, Claudin-Low, and Chemoresistant Phenotypes of Triple-Negative Breast Cancer Cells,” Int. J. Mol. Sci., vol. 23, no. 17, pp. 1–17, 2022, doi: 10.3390/ijms23179670.
XIV. C. Yun, “TIGHT JUNCTION CLAUDIN PROTEINS RESTRICT INVASIVE CANCER CELL BEHAVIORS by,” no. May, 2022.
XV. S. K. R. Zunaira Fatima, J. S. Khan2, and M. F. A. M. Farhan Haq, “Dysregulated claudin expression significantly effect breast cancer disease progression,” 2021 J. Cancer Res. Ther. | Publ. by Wolters Kluwer - Medknow, vol. 14, no. 7, pp. 1525–1534, 2022, doi: 10.4103/jcrt.JCRT.
XVI. A. Jääskeläinen, New prognostic factors and long-term prognosis of different breast cancer subtypes. 2022.
XVII. S. Nobili et al., “Establishment and characterization of a new spontaneously immortalized ER−/PR−/HER2+ human breast cancer cell line, DHSF-BR16,” Sci. Rep., vol. 11, no. 1, pp. 1–15, 2021, doi: 10.1038/s41598-021-87362-0.
XVIII. S. K. Roy, A. Shrivastava, S. Srivastav, S. Shankar, and R. K. Srivastava, “SATB2 is a novel biomarker and therapeutic target for cancer,” J. Cell. Mol. Med., vol. 24, no. 19, pp. 11064–11069, 2020, doi: 10.1111/jcmm.15755.
XIX. W. Yang et al., “Carcinoma with signet ring cell differentiation associated with invasive breast cancer: A case report,” Oncol. Lett., vol. 25, no. 5, pp. 1–7, 2023, doi: 10.3892/ol.2023.13798.
XX. S. F. Shalabi et al., “Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations,” Nat. Aging, vol. 1, no. 9, pp. 838–849, 2021, doi: 10.1038/s43587-021-00104-9.
XXI. V. Aggarwal et al., “Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement,” Semin. Cancer Biol., vol. 80, pp. 256–275, 2022,
doi: 10.1016/j.semcancer.2020.05.011.
XXII. S. Lei et al., “Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020,” Cancer Commun., vol. 41, no. 11, pp. 1183–1194, 2021, doi: 10.1002/cac2.12207.